Publications
9 results found
Jamshidiha M, Lanyon-Hogg T, Sutherell C, et al., 2021, Identification of the first structurally validated covalent ligands of the small GTPase RAB27A, RSC Medicinal Chemistry, Vol: 13, Pages: 150-155, ISSN: 2632-8682
Rab27A is a small GTPase, which mediates transport and docking of secretory vesicles at the plasma membrane via protein–protein interactions (PPIs) with effector proteins. Rab27A promotes the growth and invasion of multiple cancer types such as breast, lung and pancreatic, by enhancing secretion of chemokines, metalloproteases and exosomes. The significant role of Rab27A in multiple cancer types and the minor role in adults suggest that Rab27A may be a suitable target to disrupt cancer metastasis. Similar to many GTPases, the flat topology of the Rab27A-effector PPI interface and the high affinity for GTP make it a challenging target for inhibition by small molecules. Reported co-crystal structures show that several effectors of Rab27A interact with the Rab27A SF4 pocket (‘WF-binding pocket’) via a conserved tryptophan–phenylalanine (WF) dipeptide motif. To obtain structural insight into the ligandability of this pocket, a novel construct was designed fusing Rab27A to part of an effector protein (fRab27A), allowing crystallisation of Rab27A in high throughput. The paradigm of KRas covalent inhibitor development highlights the challenge presented by GTPase proteins as targets. However, taking advantage of two cysteine residues, C123 and C188, that flank the WF pocket and are unique to Rab27A and Rab27B among the >60 Rab family proteins, we used the quantitative Irreversible Tethering (qIT) assay to identify the first covalent ligands for native Rab27A. The binding modes of two hits were elucidated by co-crystallisation with fRab27A, exemplifying a platform for identifying suitable lead fragments for future development of competitive inhibitors of the Rab27A-effector interaction interface, corroborating the use of covalent libraries to tackle challenging targets.
Bell AS, Yu Z, Hutton JA, et al., 2020, Novel thienopyrimidine inhibitors of Leishmania N-myristoyltransferase with on-target activity in intracellular amastigotes, Journal of Medicinal Chemistry, Vol: 14, Pages: 7740-7765, ISSN: 0022-2623
The leishmaniases, caused by Leishmania species of protozoan parasites, are neglected tropical diseases with 12-15 million cases worldwide. Current therapeutic approaches are limited by toxicity, resistance and cost. N-Myristoyltransferase (NMT), an enzyme ubiquitous and essential in all eukaryotes, has been validated via genetic and pharmacological methods as a promising antileishmanial target. Here we describe a comprehensive structure activity relationship study of a thienopyrimidine series previously identified in a high throughput screen against Leishmania NMT, across 68 compounds in enzyme- and cell-based assay formats. Using a chemical tagging target engagement biomarker assay we identify the first inhibitor in this series with on-target NMT activity in leishmania parasites. Furthermore, crystal structure analyses of 12 derivatives in complex with Leishmania major NMT revealed key factors important for future structure-guided optimization delivering IMP-105 (43), a compound with modest activity against L. donovani intracellular amastigotes and excellent selectivity (>660-fold) for Leishmania NMT over human NMTs.
Lim C, Ha KP, Clarke R, et al., 2019, Identification of a potent small-molecule inhibitor of bacterial DNA repair that potentiates quinolone antibiotic activity in methicillin-resistant Staphylococcus aureus, Bioorganic and Medicinal Chemistry, Vol: 27, Pages: 1-7, ISSN: 0968-0896
The global emergence of antibiotic resistance is one of the most serious challenges facing modern medicine. There is an urgent need for validation of new drug targets and the development of small molecules with novel mechanisms of action. We therefore sought to inhibit bacterial DNA repair mediated by the AddAB/RecBCD protein complexes as a means to sensitize bacteria to DNA damage caused by the host immune system or quinolone antibiotics. A rational, hypothesis-driven compound optimization identified IMP-1700 as a cell-active, nanomolar potency compound. IMP-1700 sensitized multidrug-resistant Staphylococcus aureus to the fluoroquinolone antibiotic ciprofloxacin, where resistance results from a point mutation in the fluoroquinolone target, DNA gyrase. Cellular reporter assays indicated IMP-1700 inhibited the bacterial SOS-response to DNA damage, and compound-functionalized Sepharose successfully pulled-down the AddAB repair complex. This work provides validation of bacterial DNA repair as a novel therapeutic target and delivers IMP-1700 as a tool molecule and starting point for therapeutic development to address the pressing challenge of antibiotic resistance.
Lovell S, Sutherell CL, Tate EW, 2019, Chemical Probes for Proteins and Networks, MASS SPECTROMETRY-BASED CHEMICAL PROTEOMICS, Pages: 127-158
Sutherell CL, Ley SV, 2017, On the Synthesis and Reactivity of 2,3-Dihydropyrrolo[1,2-<i>a</i>]quinazolin-5(1<i>H</i>)-ones, SYNTHESIS-STUTTGART, Vol: 49, Pages: 135-144, ISSN: 0039-7881
- Author Web Link
- Cite
- Citations: 9
Tallant C, Sutherell CL, Siejka P, et al., 2016, Crystal structure of the fifth bromodomain of human PB1 in complex with compound 10
Tallant C, Sutherell CL, Siejka P, et al., 2016, Crystal structure of the fifth bromodomain of human PB1 in complex with compound 18
Sutherell CL, Tallant C, Monteiro OP, et al., 2016, Identification and Development of 2,3-Dihydropyrrolo[1,2-<i>a</i>]quinazolin-5(1<i>H</i>)-one Inhibitors Targeting Bromodomains within the Switch/Sucrose Nonfermenting Complex, JOURNAL OF MEDICINAL CHEMISTRY, Vol: 59, Pages: 5095-5101, ISSN: 0022-2623
- Author Web Link
- Cite
- Citations: 43
Sutherell CL, Thompson S, Scott RTW, et al., 2012, Aryl-linked imidazolidin-2-ones as non-peptidic β-strand mimetics, CHEMICAL COMMUNICATIONS, Vol: 48, Pages: 9834-9836, ISSN: 1359-7345
- Author Web Link
- Cite
- Citations: 24
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.